Chlovelxy officially announces a new round of strategic production investment and facility expansion, marking a critical milestone in the brand’s transition from laboratory research innovation to large‑scale industrialized manufacturing. As global consumer demand for safe, transdermal joint care solutions continues to grow steadily, the upgraded production base will significantly enhance standardized output capacity of Chlovelxy’s core microneedle joint patch series, stabilize global product supply, and further support the brand’s multi‑center clinical research and overseas market layout throughout 2026 and 2027.

In recent years, joint discomfort problems caused by aging, sedentary lifestyles, sports strain and chronic mild inflammation have become increasingly prevalent across global consumer groups. Traditional joint care products face obvious industry pain points: low skin penetration, unstable efficacy experience, inconvenient daily use, and insufficient batch consistency in mass production. While Chlovelxy has achieved stable breakthroughs in formulation iteration and microneedle penetration enhancement technology through H1 2026 laboratory research and ongoing multi‑center clinical verification, limited original production capacity has restricted large‑scale market promotion and long‑term brand development. To resolve supply chain bottlenecks and match growing global market demand, Chlovelxy has launched comprehensive production upgrading and capacity expansion plans.

The newly expanded production facilities adopt upgraded dust‑free purification workshops, fully automated mold casting equipment, intelligent constant‑temperature and constant‑humidity production systems, and standardized raw material screening laboratories. Compared with traditional production lines, the new manufacturing system greatly optimizes the precision of microneedle array molding, active ingredient embedding uniformity, and dissolvable matrix solidification stability. The standardized automated process effectively reduces manual errors, improves batch consistency of finished products, and ensures that every patch maintains consistent transdermal delivery performance and skin safety standards.

In addition to hardware upgrades, Chlovelxy has comprehensively optimized the entire production management system, including raw material traceability screening, semi‑finished product sampling testing, finished product stability inspection, and sterile packaging procedures. The new production mechanism strictly follows international cosmetic and topical care manufacturing specifications, forming a complete closed‑loop quality control system from raw material access, production processing to finished product delivery. This upgrade guarantees long‑term stability of product efficacy, shelf life and skin tolerability in global complex logistics and storage environments.

This capacity expansion focuses on supporting the mass production of Chlovelxy’s core inflammatory joint‑care microneedle patches. With the new production base officially put into operation, the brand’s annual scalable output of joint care products will be significantly increased, effectively solving the previous problems of insufficient inventory, long order cycles and unstable cross‑border supply. It will strongly support market sales layout in North America, Europe, Australia and other mainstream regions, shorten global delivery cycles, and improve overall consumer shopping experience and after‑sales guarantee capability.

From laboratory formula breakthroughs and multi‑center clinical collaborative verification to industrial production upgrading, Chlovelxy has always adhered to a rigorous brand development logic: technology first, safety priority, and quality stability as the core foundation of global expansion. The new production investment not only enhances the brand’s industrial manufacturing strength, but also builds a solid supply foundation for the subsequent launch of new iterative joint care products.

Moving forward, Chlovelxy will continue to link R&D iteration, clinical verification and intelligent manufacturing upgrades, steadily promote global brand localization supply layout, and provide more stable, safer and more professional daily joint care solutions for global users.